FDA Confirms Departure of Ronald Farkas (SRPT)
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
The FDA, in an email to StreetInsider, confirmed that reviewer Ronald Farkas left the agency. Further details regarding the departure weren’t provided.
Rumors that Farkas took a job in the private sector surfaced after the market close on Tuesday, sending shares of DMD drug developer Sarepta Therapeutics (Nasdaq: SRPT) sharply higher in afterhours trading. Farkas was critical of Sarepta’s eteplirsen and his departure is viewed by some on Wall Street as a positive sign for approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta's (SRPT) Exondys 51 covered by Humana (HUM) with prior authorization - Bloomberg
- Options with increasing volume: AKAM JNPR AKS P LOGI LEA NCR OI ALLY LN PNRA
- Twitter (TWTR) Gains on Reports Disney (DIS) Has Rekindled Buyout Interest
Create E-mail Alert Related CategoriesFDA, Hot FDA News, Rumors, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!